EIA reports larger-than-expected drop in crude oil inventories, bullish for oil prices

Oil futures experienced a slight recovery after an unexpected decline in U.S. crude oil inventories, as reported by the EIA. Despite remaining in negative territory, prices improved from earlier lows, indicating market reactions to supply changes.

The Trump administration is considering delaying cuts to biofuel import credits as refiners express concerns. This potential postponement comes amid ongoing discussions about the impact of these cuts on the refining industry, which has been vocal about its opposition to the proposed changes.

Cardinal Health's stock has reached an all-time high of 208.34 USD, marking a significant milestone for the company. This surge reflects positive investor sentiment and confidence in Cardinal Health's market performance. The achievement is reported by Investing.com.

Estee Lauder's Executive Vice President, Webster, has sold $476,000 worth of stock in the company. This transaction is part of standard executive trading practices and reflects Webster's financial decisions regarding his stake in Estee Lauder.

Saudi Arabia and the United States have established a strategic partnership focused on artificial intelligence (AI). This collaboration aims to enhance technological capabilities and foster economic ties between the two nations, reflecting a growing interest in AI development and investment.

CB Financial Services' Senior Executive Vice President, Sharp, has purchased $32,800 worth of shares in the company. This investment reflects confidence in the company's future performance and aligns with ongoing market activities.

SVP Moore of Energy Fuels has sold $389,000 worth of shares in the company. This transaction is part of standard executive trading practices and reflects Moore's financial decisions regarding his stake in Energy Fuels.

Schrödinger announced a strategic shift towards a greater focus on research and development during its presentation at the Jefferies London conference. The company aims to enhance its capabilities in drug discovery and development, aligning its operations with evolving market demands.